MedTrace Logo

Predictive Factors of Long Term Outcome in MMN

NCT04015934 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2019-07-11

No results posted yet for this study

Summary

The cornerstone treatment for multifocal motor neuropathy (MMN), a rare and disabling dysimmune neuropathy, is intravenous immunoglobulin (IVIg). The aim of this study is to identify prognostic factors of poor outcome.

Data were retrospectively collected from MNN patients in three French centers. Patients were divided into two groups: a good outcome group and a poor outcome group. Demographic, clinical, biological and nerve conduction study features of MMN patients were analyzed. Identification of prognostic factors in MMN could help develop personalized treatment.

Conditions

  • MMN

Sponsors & Collaborators

  • Centre Hospitalier Régional Metz-Thionville

    collaborator OTHER

  • Hospices Civils de Lyon

    collaborator OTHER

  • Central Hospital, Nancy, France

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2018-11-01
Completion
2019-02-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04015934 on ClinicalTrials.gov